Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 758


Metabolomics in the study of retinal health and disease.

Laíns I, Gantner M, Murinello S, Lasky-Su JA, Miller JW, Friedlander M, Husain D.

Prog Retin Eye Res. 2018 Nov 10. pii: S1350-9462(18)30021-1. doi: 10.1016/j.preteyeres.2018.11.002. [Epub ahead of print] Review.


Next-generation sequencing reveals two populations of damage-induced small RNAs at endogenous DNA double-strand breaks.

Bonath F, Domingo-Prim J, Tarbier M, Friedländer MR, Visa N.

Nucleic Acids Res. 2018 Nov 10. doi: 10.1093/nar/gky1107. [Epub ahead of print]


Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC).

Hopper JL, Dite GS, MacInnis RJ, Liao Y, Zeinomar N, Knight JA, Southey MC, Milne RL, Chung WK, Giles GG, Genkinger JM, McLachlan SA, Friedlander ML, Antoniou AC, Weideman PC, Glendon G, Nesci S; kConFab Investigators, Andrulis IL, Buys SS, Daly MB, John EM, Phillips KA, Terry MB.

Breast Cancer Res. 2018 Nov 3;20(1):132. doi: 10.1186/s13058-018-1056-1.


Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].

Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA.

Gynecol Oncol. 2018 Oct 22. pii: S0090-8258(18)31303-9. doi: 10.1016/j.ygyno.2018.10.022. [Epub ahead of print] No abstract available.


Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.

Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J.

Br J Cancer. 2018 Oct;119(9):1075-1085. doi: 10.1038/s41416-018-0271-y. Epub 2018 Oct 24.


Control of hepatic gluconeogenesis by Argonaute2.

Yan X, Wang Z, Bishop CA, Weitkunat K, Feng X, Tarbier M, Luo J, Friedländer MR, Burkhardt R, Klaus S, Willnow TE, Poy MN.

Mol Metab. 2018 Oct 9. pii: S2212-8778(18)30794-4. doi: 10.1016/j.molmet.2018.10.003. [Epub ahead of print]


Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.

N Engl J Med. 2018 Oct 21. doi: 10.1056/NEJMoa1810858. [Epub ahead of print]


Meta-analysis of the alliance-outcome relation in couple and family therapy.

Friedlander ML, Escudero V, Welmers-van de Poll MJ, Heatherington L.

Psychotherapy (Chic). 2018 Dec;55(4):356-371. doi: 10.1037/pst0000161.


Cancer of the ovary, fallopian tube, and peritoneum.

Berek JS, Kehoe ST, Kumar L, Friedlander M.

Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:59-78. doi: 10.1002/ijgo.12614.


Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial.

Macular Telangiectasia Type 2-Phase 2 CNTF Research Group, Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM, Guymer R, Rosenfeld P, Hubschman JP, Constable I, Wiley H, Singerman LJ, Gillies M, Comer G, Blodi B, Eliott D, Yan J, Bird A, Friedlander M.

Ophthalmology. 2018 Oct 4. pii: S0161-6420(18)31427-1. doi: 10.1016/j.ophtha.2018.09.041. [Epub ahead of print]


Plant microRNAs in human sera are likely contaminants.

Fromm B, Kang W, Rovira C, Cayota A, Witwer K, Friedländer MR, Tosar JP.

J Nutr Biochem. 2018 Sep 5. pii: S0955-2863(18)30535-7. doi: 10.1016/j.jnutbio.2018.07.019. [Epub ahead of print] No abstract available.


Correction: Antibody targeting TSPAN12/β-catenin signaling in vasoproliferative retinopathy.

Bucher F, Friedlander M, Yea K.

Oncotarget. 2018 Sep 4;9(69):33244. doi: 10.18632/oncotarget.26102. eCollection 2018 Sep 4.


microRNA-205-5p is a modulator of insulin sensitivity that inhibits FOXO function.

Langlet F, Tarbier M, Haeusler RA, Camastra S, Ferrannini E, Friedländer MR, Accili D.

Mol Metab. 2018 Nov;17:49-60. doi: 10.1016/j.molmet.2018.08.003. Epub 2018 Aug 11.


Medicare-funded cancer genetic tests: a note of caution.

Kirk J, Barlow-Stewart KK, Poplawski NK, Gleeson M, Tucker K, Friedlander M.

Med J Aust. 2018 Aug 3;209(5):193-196. No abstract available.


Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.

Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA.

Gynecol Oncol. 2018 Oct;151(1):18-23. doi: 10.1016/j.ygyno.2018.07.021. Epub 2018 Aug 19. Erratum in: Gynecol Oncol. 2018 Oct 22;:.


PURL: Time to switch to nonsterile gloves for these procedures?

Castelli G, Friedlander MP.

J Fam Pract. 2018 Aug;67(8):507-508.


Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis.

Sjoquist KM, Lord SJ, Friedlander ML, John Simes R, Marschner IC, Lee CK.

Ther Adv Med Oncol. 2018 Aug 6;10:1758835918788500. doi: 10.1177/1758835918788500. eCollection 2018.


Toward a nuanced understanding of nondisclosure in psychotherapy supervision.

Gibson AS, Ellis MV, Friedlander ML.

J Couns Psychol. 2018 Aug 2. doi: 10.1037/cou0000295. [Epub ahead of print]


Illustrating novel techniques for analyzing single-case experiments: Effects of pre-session mindfulness practice.

Stone M, Friedlander ML, Moeyaert M.

J Couns Psychol. 2018 Nov;65(6):690-702. doi: 10.1037/cou0000291. Epub 2018 Jul 30.


Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.

Meagher NS, Schuster K, Voss A, Budden T, Pang CNI, deFazio A, Ramus SJ, Friedlander ML.

Gynecol Oncol. 2018 Sep;150(3):527-533. doi: 10.1016/j.ygyno.2018.07.013. Epub 2018 Jul 25.


Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.

Friedlander M, Gebski V, Gibbs E, Davies L, Bloomfield R, Hilpert F, Wenzel LB, Eek D, Rodrigues M, Clamp A, Penson RT, Provencher D, Korach J, Huzarski T, Vidal L, Salutari V, Scott C, Nicoletto MO, Tamura K, Espinoza D, Joly F, Pujade-Lauraine E.

Lancet Oncol. 2018 Aug;19(8):1126-1134. doi: 10.1016/S1470-2045(18)30343-7. Epub 2018 Jul 17.


A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer.

Wilson MK, Mercieca-Bebber R, Friedlander M.

J Gynecol Oncol. 2018 Sep;29(5):e81. doi: 10.3802/jgo.2018.29.e81. Epub 2018 Jun 9. Review.


Voices from the Field: Supporting the Educational Needs of Cytotechnologists.

Friedlander MA, Pineault LS, Donnelly A, Giroux S, Naik K.

Lab Med. 2018 Jul 5;49(3):e41-e51. doi: 10.1093/labmed/lmy041.


Perspectives on Expanded Scope of Practice in Cytotechnology.

Friedlander MA, Pineault LS, Roberson J, Spiczka AW.

Lab Med. 2018 Jul 5;49(3):e52-e61. doi: 10.1093/labmed/lmy042.


Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer.

Beesley VL, Smith DD, Nagle CM, Friedlander M, Grant P, DeFazio A, Webb PM; OPAL Study Group.

Support Care Cancer. 2018 Dec;26(12):4133-4142. doi: 10.1007/s00520-018-4284-0. Epub 2018 Jun 12.


Concordance of illness perceptions: The key to improving care of medically unexplained symptoms.

McAndrew LM, Friedlander ML, Alison Phillips L, L Santos S, Helmer DA.

J Psychosom Res. 2018 Aug;111:140-142. doi: 10.1016/j.jpsychores.2018.05.015. Epub 2018 May 25. No abstract available.


Antibody targeting TSPAN12/β-catenin signaling in vasoproliferative retinopathy.

Bucher F, Friedlander M, Yea K.

Oncotarget. 2017 Dec 18;9(16):12538-12539. doi: 10.18632/oncotarget.23401. eCollection 2018 Feb 27. No abstract available. Erratum in: Oncotarget. 2018 Sep 4;9(69):33244.


Paternal high-fat diet enhances offspring whole-body insulin sensitivity and skeletal muscle insulin signaling early in life.

Consitt LA, Saxena G, Slyvka Y, Clark BC, Friedlander M, Zhang Y, Nowak FV.

Physiol Rep. 2018 Mar;6(5). doi: 10.14814/phy2.13583.


Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.

Ritchie G, Gasper H, Man J, Lord S, Marschner I, Friedlander M, Lee CK.

JAMA Oncol. 2018 Apr 1;4(4):522-528. doi: 10.1001/jamaoncol.2017.5236.


Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries.

Oskay-Özcelik G, Alavi S, Richter R, Keller M, Chekerov R, Cecere SC, Cormio G, Joly F, Kurtz JE, du Bois A, Maciejewski M, Jedryka M, Vergote I, Van Nieuwenhuysen E, Casado A, Mendiola C, Achimas-Cadariu P, Vlad C, Reimer D, Zeimet AG, Friedlander M, Sehouli J.

Ann Oncol. 2018 Apr 1;29(4):910-916. doi: 10.1093/annonc/mdy037.


Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy.

Sousa M, Peate M, Lewis C, Jarvis S, Willis A, Hickey M, Friedlander M.

Eur J Cancer Care (Engl). 2018 Mar;27(2):e12820. doi: 10.1111/ecc.12820. Epub 2018 Jan 16.


Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.

Friedlander M, Rau J, Lee CK, Meier W, Lesoin A, Kim JW, Poveda A, Buck M, Scambia G, Shimada M, Hilpert F, King MT, Debruyne P, Bologna A, Malander S, Monk BJ, Petru E, Calvert P, Herzog TJ, Barrett C, du Bois A.

Ann Oncol. 2018 Mar 1;29(3):737-743. doi: 10.1093/annonc/mdx796.


Fully automated, deep learning segmentation of oxygen-induced retinopathy images.

Xiao S, Bucher F, Wu Y, Rokem A, Lee CS, Marra KV, Fallon R, Diaz-Aguilar S, Aguilar E, Friedlander M, Lee AY.

JCI Insight. 2017 Dec 21;2(24). pii: 97585. doi: 10.1172/jci.insight.97585. [Epub ahead of print]


Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.

King MT, Stockler MR, O'Connell RL, Buizen L, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Sehouli J, Feeney A, Berton-Rigaud D, Costa DSJ, Friedlander ML; GCIG Symptom Benefit group.

Qual Life Res. 2018 Jan;27(1):59-74. doi: 10.1007/s11136-017-1729-8. Epub 2017 Dec 16.


Global Connections to Study Idiopathic Macular Telangiectasia Type 2.

Chew EY, Friedlander M.

Retina. 2018 Jan;38 Suppl 1:S3-S7. doi: 10.1097/IAE.0000000000001921. No abstract available.


Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.

Heinzelmann-Schwarz V, Knipprath Mészaros A, Stadlmann S, Jacob F, Schoetzau A, Russell K, Friedlander M, Singer G, Vetter M.

Gynecol Oncol. 2018 Jan;148(1):79-85. doi: 10.1016/j.ygyno.2017.10.036. Epub 2017 Nov 20.


A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.

Wilson MK, Friedlander ML, Joly F, Oza AM.

Oncologist. 2018 Feb;23(2):203-213. doi: 10.1634/theoncologist.2017-0297. Epub 2017 Nov 8. Review.


Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.

Park SB, Kwok JB, Asher R, Lee CK, Beale P, Selle F, Friedlander M.

Ann Oncol. 2017 Nov 1;28(11):2733-2740. doi: 10.1093/annonc/mdx491.


Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).

Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M.

Gynecol Oncol. 2018 Jan;148(1):36-41. doi: 10.1016/j.ygyno.2017.10.019. Epub 2017 Oct 26.


Novel Modification of HistoGel-Based Cell Block Preparation Method: Improved Sufficiency for Molecular Studies.

Rekhtman N, Buonocore DJ, Rudomina D, Friedlander M, Dsouza C, Aggarwal G, Arcila M, Edelweiss M, Lin O.

Arch Pathol Lab Med. 2018 Apr;142(4):529-535. doi: 10.5858/arpa.2017-0030-OA. Epub 2017 Nov 2.


Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.

Garsed DW, Alsop K, Fereday S, Emmanuel C, Kennedy CJ, Etemadmoghadam D, Gao B, Gebski V, Garès V, Christie EL, Wouters MCA, Milne K, George J, Patch AM, Li J, Arnau GM, Semple T, Gadipally SR, Chiew YE, Hendley J, Mikeska T, Zapparoli GV, Amarasinghe K, Grimmond SM, Pearson JV, Waddell N, Hung J, Stewart CJR, Sharma R, Allan PE, Rambau PF, McNally O, Mileshkin L, Hamilton A, Ananda S, Grossi M, Cohen PA, Leung YC, Rome RM, Beale P, Blomfield P, Friedlander M, Brand A, Dobrovic A, Köbel M, Harnett P, Nelson BH, Bowtell DDL, deFazio A; Nadia Traficante, for the Australian Ovarian Cancer Study Group.

Clin Cancer Res. 2018 Feb 1;24(3):569-580. doi: 10.1158/1078-0432.CCR-17-1621. Epub 2017 Oct 23.


Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.

Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S.

Ann Oncol. 2018 Jan 1;29(1):154-161. doi: 10.1093/annonc/mdx505.


Signatures of positive selection reveal a universal role of chromatin modifiers as cancer driver genes.

Zapata L, Susak H, Drechsel O, Friedländer MR, Estivill X, Ossowski S.

Sci Rep. 2017 Oct 13;7(1):13124. doi: 10.1038/s41598-017-12888-1.


Correlation Between Macular Integrity Assessment and Optical Coherence Tomography Imaging of Ellipsoid Zone in Macular Telangiectasia Type 2.

Mukherjee D, Lad EM, Vann RR, Jaffe SJ, Clemons TE, Friedlander M, Chew EY, Jaffe GJ, Farsiu S; MacTel Study Group.

Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO291-BIO299. doi: 10.1167/iovs.17-21834.


Differential Impact of Glucose Administered Intravenously and Orally on Circulating miR-375 Levels in Human Subjects.

Yan X, Wang Z, Westberg-Rasmussen S, Tarbier M, Rathjen T, Tattikota SG, Peck BCE, Kanke M, Oxvig C, Frystyk J, Starup-Linde J, Sethupathy P, Friedländer MR, Gregersen S, Poy MN.

J Clin Endocrinol Metab. 2017 Oct 1;102(10):3749-3755. doi: 10.1210/jc.2017-01365.


The acute effects of ultraviolet radiation on the blood transcriptome are independent of plasma 25OHD3.

Bustamante M, Hernandez-Ferrer C, Sarria Y, Harrison GI, Nonell L, Kang W, Friedländer MR, Estivill X, González JR, Nieuwenhuijsen M, Young AR.

Environ Res. 2017 Nov;159:239-248. doi: 10.1016/j.envres.2017.07.045. Epub 2017 Sep 18.


Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.

Lee YC, Milne RL, Lheureux S, Friedlander M, McLachlan SA, Martin KL, Bernardini MQ, Smith C, Picken S, Nesci S, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).

Eur J Cancer. 2017 Oct;84:114-120. doi: 10.1016/j.ejca.2017.07.004. Epub 2017 Aug 10.


Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators.

Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25. Erratum in: Lancet Oncol. 2017 Sep;18(9):e510.


Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required.

Pickett JL, Chou A, Andrici JA, Clarkson A, Sioson L, Sheen A, Reagh J, Najdawi F, Kim Y, Riley D, Maidens J, Nevell D, McIlroy K, Valmadre S, Gard G, Hogg R, Turchini J, Robertson G, Friedlander M, Gill AJ.

Am J Surg Pathol. 2017 Oct;41(10):1433-1442. doi: 10.1097/PAS.0000000000000909.


Resisting RECIST-Uniformity Versus Clinical Validity.

Wilson MK, Friedlander ML, Lheureux S, Small W Jr, Poveda A, Pujade-Lauraine E, Karakasis K, Bacon M, Bowering V, Chawla T, Oza AM.

Int J Gynecol Cancer. 2017 Oct;27(8):1619-1627. doi: 10.1097/IGC.0000000000001062.


Supplemental Content

Loading ...
Support Center